As of 15:02 TST, July 30, 2026 | Primary review period: July 29, 2026 15:00 – July 30, 2026 15:02 | Additional coverage: significant transactions not captured in the prior digest

The day's headline transaction is Intercontinental Exchange's agreement to acquire bond-trading platform MarketAxess at an enterprise value of approximately $5.7 billion — a 33% premium to the prior closing price. The U.S. deal flow also includes Procore's $845 million acquisition of DroneDeploy, Johnson & Johnson's completion of its $1 billion purchase of Firefly Bio, and J&J's strategic investment in Sail Biomedicines with a $2.58 billion exclusive acquisition option.

In Turkey, ICU Girişim Sermayesi Yatırım Ortaklığı's lead shareholder signed a binding share transfer agreement to convey all 11,250,000 Class A preferred shares to DANİSTA Finansal Danışmanlık Hizmetleri A.Ş. for approximately TRY 37.8 million. The transaction has not yet closed and remains subject to CMB approval and other conditions.

The shares being transferred represent the entirety of the Class A preferred shares held by ICU Girişim's current lead shareholder. ICU Girişim itself is not a direct party to the share transfer agreement. Closing is subject to the conditions set out in the agreement, the CMB process, and any other required approvals, consents, and notifications.

A prior letter of intent for the same shares — under which OTTO Holding had been the prospective buyer — was terminated before any share transfer occurred. The binding agreement with DANİSTA therefore supersedes the OTTO process with respect to these shares.

Legal and commercial significance: The transfer of the entire preferred share block may result in a change of lead shareholder and influence over management at ICU Girişim. Whether legal control of management changes will depend on the voting rights, board nomination privileges, and post-closing ownership structure associated with these shares.

Practice considerations: The CMB's requirements regarding lead shareholder status and ownership structure, the buyer's financial adequacy, and corporate governance framework should be reviewed. If the transfer results in acquisition of management control, mandatory tender offer obligations or available exemptions should be separately assessed. The mutual release, confidentiality, information use, and any surviving priority rights arising from the terminated OTTO process should also be confirmed.

ICE will acquire all outstanding shares of MarketAxess in an all-cash transaction. The offer price represents a 33% premium to MarketAxess's closing price on July 29. MarketAxess connects approximately 2,100 institutional investors and broker-dealers across more than 90 countries in the markets for corporate bonds, municipal bonds, emerging market debt, Eurobonds, and U.S. Treasuries.

The acquisition will be financed with new debt. ICE expects approximately $100 million in annual cost synergies and accretion to adjusted earnings per share in the first full year following closing. Closing is subject to MarketAxess shareholder approval, regulatory clearances, and customary closing conditions.

Legal and commercial significance: The transaction consolidates MarketAxess's institutional bond trading network with ICE's bond platform, pricing data, indices, and analytics products serving retail and asset management clients under a single structure. This is therefore not merely a trading platform acquisition but a vertical capital markets consolidation spanning pre-trade price discovery through post-trade data and compliance services.

Practice considerations: Merger control review will likely examine not only electronic bond trading volumes but also access to transaction data, index and pricing products, continued servicing of competing platforms, and client routing capabilities. Detailed behavioral remedies addressing cross-platform use of client data, fair and non-discriminatory access, market surveillance, and intra-group conflicts of interest may be required. Given debt financing, the duration of financing commitments, the long-stop date, and regulatory delay risk should be aligned with the transaction documents.

Procore signed a definitive agreement to acquire DroneDeploy, which is used across more than 180 countries and over three million job sites. DroneDeploy enables continuous three-dimensional monitoring of construction sites using imagery from drones, ground robots, mobile devices, fixed cameras, and wearables.

The combined system will match Procore's project documentation and decision records with DroneDeploy's physical site imagery. Procore's database holds approximately 400 million photos and more than 126 million drawings; DroneDeploy holds approximately 20 trillion square feet of visual field data. The transaction is subject to required regulatory approvals and customary closing conditions.

Legal and commercial significance: The transaction combines construction management software with robotic and imaging infrastructure that directly observes the physical job site. Procore aims to evolve from a platform that records project data into an AI system that automatically identifies delays, defects, and safety risks in the field.

Practice considerations: Due diligence should focus on drone flight permits, ownership of site imagery, data use consents obtained from employers and contractors, critical infrastructure imagery, cybersecurity, and training rights for AI models. Software licenses, open-source components, change-of-control provisions in customer contracts, and the evidentiary status of imagery should also be addressed during integration.

Johnson & Johnson completed the acquisition of Firefly Bio on July 29, 2026. Firefly's Firelink platform aims to deliver protein-degrading drugs directly to cancer cells via antibodies, targeting in particular KRAS-associated solid tumors.

The transaction will be recorded as an asset acquisition rather than a business combination for accounting purposes, causing Johnson & Johnson to recognize approximately $1 billion in in-process research and development expense in the third quarter of 2026. The company expects the transaction to reduce 2026 earnings per share by approximately $0.46.

Legal and commercial significance: A significant portion of the acquisition price derives not from existing commercial revenues but from an early-stage technology platform, patents, and future drug candidates. Clinical and intellectual property risk has therefore passed entirely to Johnson & Johnson upon closing.

Practice considerations: The patent chain, university or researcher licenses, royalty obligations, integrity of clinical data, FDA correspondence, and transfer of manufacturing technology should be prioritized. Retention of key scientists and clear allocation of inventorship in products developed from the platform post-closing are required.

Johnson & Johnson will invest in Sail and develop the company's in vivo CAR-T platform, which aims to reprogram immune cells directly within the patient's body to address autoimmune diseases. Johnson & Johnson also obtained an exclusive option to acquire Sail for $2.58 billion.

Legal and commercial significance: The structure allows the acquirer to make a minority investment in a biotechnology company with high clinical and regulatory risk, monitor the program's development, and decide on full acquisition once certain conditions are met — rather than assuming full risk immediately.

Practice considerations: The option exercise period and conditions, whether the acquisition price is subject to adjustment, financing of clinical programs, licensing of intellectual property to third parties, and restrictions on Sail's ability to transact with other investors during the option period should be carefully documented. Johnson & Johnson's information and veto rights as a minority investor must be structured so as not to create de facto control or premature integration prior to closing.

Raft develops open-architecture software that fuses data from disparate sensors and systems into a common operational picture. Leonardo DRS will combine Raft's AI and data integration capabilities with its existing sensors, network computing, and defense systems.

Legal and commercial significance: The transaction enables vertical integration of defense hardware and mission software, allowing Leonardo DRS to offer not only sensors and hardware but also software solutions that analyze data from those systems.

Practice considerations: Transfer or novation of government contracts, security clearances, protection of classified data, data rights in government-funded software, and export controls are the primary review areas. Retention of key software developers, open-source code usage, and open-architecture commitments made to government customers will also be significant in post-acquisition integration.

The portfolio consists of industrial properties in high-growth markets including Austin, Dallas, Phoenix, Charlotte, and Central Florida, with an occupancy rate of approximately 95%. The transaction was financed with debt provided by JPMorgan and Wells Fargo.

Legal and commercial significance: This is a large-scale real estate portfolio acquisition rather than a corporate share transfer. However, the multi-state location of the assets, the involvement of multiple tenants and property companies, and their simultaneous transfer require a closing and financing structure comparable in complexity to corporate M&A transactions.

Practice considerations: Title and lien review, environmental due diligence, tenant estoppel certificates, assignment provisions in lease agreements, property taxes, and insurance coverage should be verified on a building-by-building basis. Cross-default provisions and the effect of a default on one property on the remaining portfolio should be limited in the portfolio financing structure.

No newly signed Turkish buyer–U.S. target or U.S. buyer–Turkish target transaction was identified in publicly available and verifiable sources during the review period. No new overseas acquisition by a Turkish company or significant spin-off transaction was confirmed.

The primary Turkey-side development of the period is the potential control change at ICU Girişim through the preferred share transfer. U.S. deal flow was concentrated in capital markets infrastructure, construction technology, biotechnology, defense software, and industrial real estate.